Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Stadler

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
International Journal of Oncology|August 12, 2000
A G2/M growth arrest response to low-dose intermittent H2O2 in normal uroepithelial cellsM Chien, C Rinker-Schaeffer, W M Stadler
Urology|December 18, 2001
Nilutamide: possible utility as a second-line hormonal agentA Desai, W M Stadler, N J Vogelzang
The Journal of Urology|March 21, 1998
Expression of bcl-2 and bcl-X in bladder cancerE J Kirsh, D A Baunoch, W M Stadler
Seminars in Oncology|October 31, 2001
Docetaxel and exisulind in hormone-refractory prostate cancerC W Ryan, W M Stadler, N J Vogelzang
Journal of the National Cancer Institute|December 2, 1992
Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicatorW M Stadler, J M Richards, N J Vogelzang
Cancer|November 1, 1995
A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinomaW M Stadler, M E Rybak, N J Vogelzang
Urology|February 1, 1996
High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experienceK L Shulman, W M Stadler, N J Vogelzang
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2011
Novel approaches and future directions in castration-resistant prostate cancerC Nabhan, B Parsons, E Z Touloukian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinomaW M Stadler, T Kuzel, M Dumas, et al.
Current Oncology Reports|December 21, 2000
Angiogenesis inhibitorsT R Tennant, C W Rinker-Schaeffer, W M Stadler
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
International Journal of Oncology|August 12, 2000
A G2/M growth arrest response to low-dose intermittent H2O2 in normal uroepithelial cellsM Chien, C Rinker-Schaeffer, W M Stadler
Urology|December 18, 2001
Nilutamide: possible utility as a second-line hormonal agentA Desai, W M Stadler, N J Vogelzang
The Journal of Urology|March 21, 1998
Expression of bcl-2 and bcl-X in bladder cancerE J Kirsh, D A Baunoch, W M Stadler
Seminars in Oncology|October 31, 2001
Docetaxel and exisulind in hormone-refractory prostate cancerC W Ryan, W M Stadler, N J Vogelzang
Journal of the National Cancer Institute|December 2, 1992
Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicatorW M Stadler, J M Richards, N J Vogelzang
Cancer|November 1, 1995
A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinomaW M Stadler, M E Rybak, N J Vogelzang
Urology|February 1, 1996
High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experienceK L Shulman, W M Stadler, N J Vogelzang
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2011
Novel approaches and future directions in castration-resistant prostate cancerC Nabhan, B Parsons, E Z Touloukian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinomaW M Stadler, T Kuzel, M Dumas, et al.
Current Oncology Reports|December 21, 2000
Angiogenesis inhibitorsT R Tennant, C W Rinker-Schaeffer, W M Stadler
Pageof 7